Top Page
Zai Lab Ltd
(Frankfurt:9688)
Zai Lab Ltd (9688) vs. iShares MSCI Hong Kong ETF (EWH)
Zai Lab Ltd Business Overview & Revenue Model
Zai Lab Ltd Financial Statement Overview
| Breakdown | |||||
| TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 418.33M | 398.99M | 266.72M | 215.04M | 144.31M | 48.96M | Gross Profit |
| 265.44M | 251.13M | 170.90M | 141.02M | 92.07M | 32.22M | EBIT |
| -268.12M | -282.12M | -366.57M | -404.36M | -700.06M | -301.80M | EBITDA |
| -236.44M | -242.99M | -365.11M | -384.66M | -689.46M | -262.96M | Net Income Common Stockholders |
| -252.07M | -257.10M | -334.62M | -481.99M | -692.44M | -298.16M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 757.26M | 779.67M | 806.45M | 1.01B | 1.41B | 1.19B | Total Assets |
| 1.17B | 1.19B | 1.04B | 1.22B | 1.61B | 1.30B | Total Debt |
| 192.30M | 153.47M | 15.15M | 20.39M | 15.54M | 18.60M | Net Debt |
| -564.97M | -296.20M | -775.00M | -988.08M | -948.56M | -423.52M | Total Liabilities |
| 362.58M | 344.86M | 240.18M | 174.54M | 230.00M | 128.29M | Stockholders Equity |
| 810.75M | 840.90M | 796.12M | 1.05B | 1.38B | 1.17B |
| Cash Flow | Free Cash Flow | ||||
| -238.84M | -276.39M | -206.67M | -392.63M | -568.18M | -226.72M | Operating Cash Flow |
| -186.46M | -214.87M | -198.18M | -367.64M | -549.23M | -216.06M | Investing Cash Flow |
| -52.35M | -375.19M | -10.78M | 420.02M | 249.96M | -554.83M | Financing Cash Flow |
| 345.48M | 349.89M | -6.43M | -1.73M | 820.20M | 1.13B |
Zai Lab Ltd Technical Analysis
Zai Lab Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | $56.13B | 24.91 | 14.19% | 1.13% | 14.36% | 33.22% | |
74 Outperform | HK$113.92B | 31.58 | 8.17% | ― | 7.52% | -1.92% | |
68 Neutral | HK$267.85B | ― | -11.43% | ― | 50.53% | 50.84% | |
67 Neutral | $14.49B | 28.82 | 3.53% | ― | -3.12% | -12.71% | |
62 Neutral | HK$3.78B | 21.21 | 4.47% | ― | -9.75% | ― | |
58 Neutral | HK$36.50B | ― | -32.29% | ― | 43.13% | 28.93% | |
54 Neutral | $5.38B | 3.27 | -45.10% | 3.30% | 16.81% | 0.02% |
Zai Lab Ltd Corporate Events
Zai Lab Ltd announced the granting of share options and restricted share units under its 2024 Equity Incentive Plan. On June 3, 2025, the company granted options to subscribe for 2,500 American Depositary Shares (ADSs) to one employee and restricted share units covering 4,104 ADSs to three employees. This move is part of Zai Lab’s strategy to align employee incentives with company performance, although the grants do not include performance targets or clawback mechanisms. The compensation committee believes this approach is market competitive and consistent with the company’s customary practices.
The most recent analyst rating on (HK:9688) stock is a Buy with a HK$24.34 price target. To see the full list of analyst forecasts on Zai Lab Ltd stock, see the HK:9688 Stock Forecast page.
Zai Lab Ltd announced the grant of 9,800 Restricted Share Units to two employees under its 2024 Equity Incentive Plan. This initiative aims to recognize and reward the employees’ contributions and incentivize their continued efforts towards the company’s success. The grants, which have no performance targets or clawback mechanisms, are seen as market competitive and aligned with the company’s practices, potentially enhancing employee retention and motivation.
The most recent analyst rating on (HK:9688) stock is a Buy with a HK$24.34 price target. To see the full list of analyst forecasts on Zai Lab Ltd stock, see the HK:9688 Stock Forecast page.
Zai Lab Limited reported a 22% year-over-year increase in total revenues for the first quarter of 2025, reaching $106.5 million, and is on track to achieve profitability by the fourth quarter of 2025. The company is advancing its oncology pipeline with promising data presentations and is poised for growth with a strong cash position and expanding global portfolio, aiming to drive long-term shareholder value.
Zai Lab Limited announced the filing of its Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, with the U.S. Securities and Exchange Commission. This filing is part of the company’s regulatory compliance and provides stakeholders with updated financial and operational information, potentially impacting its market positioning and investor relations.
Zai Lab Ltd has announced its 2025 annual general meeting of shareholders, scheduled for June 18, 2025, in Shanghai and virtually. The meeting will address several key resolutions, including the re-election of directors, the appointment of KPMG as auditors, and the approval of executive compensation and share issuance mandates, which are crucial for the company’s governance and strategic planning.
Zai Lab Limited has announced that its Audit Committee will review and approve the company’s unaudited quarterly results for the first quarter of 2025 on May 8, 2025. The results, prepared in accordance with U.S. GAAP and SEC rules, will be published on the same day. Following the release, the company will host a live earnings call and webcast to discuss the results, providing an opportunity for stakeholders to engage with the company’s management.
Zai Lab Limited has filed preliminary proxy materials with the U.S. Securities and Exchange Commission for its 2025 annual general meeting. The agenda includes the re-election of directors, approval of auditor appointments, and authorization for the board to manage share allotments and repurchases. This filing is a regulatory step towards the annual meeting, reflecting Zai Lab’s commitment to corporate governance and shareholder engagement.
Zai Lab Limited announced the grant of share options, restricted share units, and performance share units under its 2024 Equity Incentive Plan. The grants include 204,650 options to 40 employees, 420,100 restricted share units to 381 employees, and 32,975 performance share units to 4 employees. This initiative is part of the company’s strategy to align employee interests with corporate goals and maintain competitive compensation practices.
Zai Lab Limited reported a 49% increase in net product revenue for 2024, reaching $397.6 million, driven by the successful launch and sales of VYVGART, as well as increased sales of ZEJULA and NUZYRA. The company also saw a 23% reduction in net loss to $257.1 million, attributed to revenue growth outpacing operating expenses, despite challenges such as decreased interest income and increased foreign currency loss.
Zai Lab Limited has announced that its board of directors will review and approve the company’s annual results for the year ended December 31, 2024, in accordance with the Hong Kong Listing Rules. These results, which align with the previously announced U.S. GAAP results filed with the SEC, will include additional disclosures required by Hong Kong regulations and a reconciliation to International Financial Reporting Standards. This action underscores Zai Lab’s commitment to transparency and regulatory compliance, potentially impacting its market perception and stakeholder confidence.